ID   NALM-1
AC   CVCL_0091
SY   Nalm-1; NALM 1; NALM1; Nalm1
DR   CLO; CLO_0007937
DR   EFO; EFO_0002244
DR   CLDB; cl3630
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CRL-1567
DR   BioSample; SAMN01821583
DR   BioSample; SAMN01821650
DR   BioSample; SAMN03471397
DR   BioSample; SAMN10988498
DR   CCLE; NALM1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   CGH-DB; 9216-4
DR   Cosmic; 787506
DR   Cosmic; 801721
DR   Cosmic; 908157
DR   Cosmic; 999775
DR   Cosmic; 1012105
DR   Cosmic; 1026573
DR   Cosmic; 1498418
DR   Cosmic; 2491099
DR   DepMap; ACH-000462
DR   DSMZ; ACC-131
DR   GEO; GSM887346
DR   GEO; GSM888422
DR   IGRhCellID; NALM1
DR   JCRB; JCRB0064
DR   LiGeA; CCLE_447
DR   PharmacoDB; NALM1_978_2019
DR   Wikidata; Q54907391
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=301573;
RX   PubMed=302341;
RX   PubMed=2140233;
RX   PubMed=3332852;
RX   PubMed=6582512;
RX   PubMed=6929725;
RX   PubMed=9067587;
RX   PubMed=9680106;
RX   PubMed=12506034;
RX   PubMed=15588857;
RX   PubMed=15843827;
RX   PubMed=16408098;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=30285677;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Doubling time: ~48 hours (DSMZ).
CC   Sequence variation: BCR-ABL1 gene fusion (PubMed=15843827).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=77.03%; Native American=6.08%; East Asian, North=2.94%; East Asian, South=0%; South Asian=0%; European, North=4.83%; European, South=9.12% (PubMed=30894373).
CC   Discontinued: JCRB; JCRB0064; probable.
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): ATCC; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11,12
ST   D16S539: 11,15
ST   D5S818: 11
ST   D7S820: 10,11
ST   TH01: 7,9
ST   TPOX: 9,11
ST   vWA: 15,17
DI   NCIt; C7320; Childhood chronic myelogenous leukemia, BCR-ABL1 positive
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   3Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 23
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=301573; DOI=10.1093/jnci/59.1.83;
RA   Minowada J., Tsubota T., Greaves M.F., Walters T.R.;
RT   "A non-T, non-B human leukemia cell line (NALM-1): establishment of
RT   the cell line and presence of leukemia-associated antigens.";
RL   J. Natl. Cancer Inst. 59:83-87(1977).
//
RX   PubMed=302341; DOI=10.1093/jnci/59.3.833;
RA   Sonta S.-I., Minowada J., Tsubota T., Sandberg A.A.;
RT   "Cytogenetic study of a new Ph1-positive cell line (NALM-1).";
RL   J. Natl. Cancer Inst. 59:833-837(1977).
//
RX   PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x;
RA   Nakano A., Harada T., Morikawa S., Kato Y.;
RT   "Expression of leukocyte common antigen (CD45) on various human
RT   leukemia/lymphoma cell lines.";
RL   Acta Pathol. Jpn. 40:107-115(1990).
//
RX   PubMed=3332852; DOI=10.1016/S0950-3536(87)80037-9;
RA   Keating A.;
RT   "Ph positive CML cell lines.";
RL   Baillieres Clin. Haematol. 1:1021-1029(1987).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=6929725; DOI=10.1002/1097-0142(19800501)45:9<2324::AID-CNCR2820450915>3.0.CO;2-J;
RA   Kubonishi I., Freeman A.I., Minowada J.;
RT   "Heterotransplantation and clonal growth of human
RT   Ph'-chromosome-positive leukemia-cell (NALM-1) and B-cell
RT   leukemia-cell (BALM-2) lines.";
RL   Cancer 45:2324-2329(1980).
//
RX   PubMed=9067587; DOI=10.1038/sj.leu.2400571;
RA   Uphoff C.C., MacLeod R.A.F., Denkmann S.A., Golub T.R., Borkhardt A.,
RA   Janssen J.W.G., Drexler H.G.;
RT   "Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in
RT   human early B-lineage leukemia cell lines.";
RL   Leukemia 11:441-447(1997).
//
RX   PubMed=9680106; DOI=10.1016/S0145-2126(98)00050-2;
RA   Matsuo Y., Drexler H.G.;
RT   "Establishment and characterization of human B cell precursor-leukemia
RT   cell lines.";
RL   Leuk. Res. 22:567-579(1998).
//
RX   PubMed=12506034; DOI=10.1182/blood-2002-06-1770;
RA   Uno K., Inukai T., Kayagaki N., Goi K., Sato H., Nemoto A.,
RA   Takahashi K., Kagami K., Yamaguchi N., Yagita H., Okumura K.,
RA   Koyama-Okazaki T., Suzuki T., Sugita K., Nakazawa S.;
RT   "TNF-related apoptosis-inducing ligand (TRAIL) frequently induces
RT   apoptosis in Philadelphia chromosome-positive leukemia cells.";
RL   Blood 101:3658-3667(2003).
//
RX   PubMed=15588857; DOI=10.1016/j.cancergencyto.2004.04.021;
RA   Pelz A.-F., Weilepp G., Wieacker P.F.;
RT   "Re-analysis of the cell line NALM-1 karyotype by GTG-banding,
RT   spectral karyotyping, and whole chromosome painting.";
RL   Cancer Genet. Cytogenet. 156:59-61(2005).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940-940(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//